|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li Z, Lei H, Luo M, Wang Y, Dong L, Ma Y,
Liu C, Song W, Wang F, Zhang J, et al: DNA methylation
downregulated mir-10b acts as a tumor suppressor in gastric cancer.
Gastric Cancer. 18:43–54. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Qiu T, Zhou X, Wang J, Du Y, Xu J, Huang
Z, Zhu W, Shu Y and Liu P: miR-145, miR-133a and miR-133b inhibit
proliferation, migration, invasion and cell cycle progression via
targeting transcription factor Sp1 in gastric cancer. FEBS Lett.
588:1168–1177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
John B, Enright AJ, Aravin A, Tuschl T,
Sander C and Marks DS: Human MicroRNA targets. PLoS Biol.
2:e3632004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lu C, Shan Z, Li C and Yang L: miR-129
regulates cisplatin-resistance in human gastric cancer cells by
targeting P-gp. Biomed Pharmacother. 86:450–456. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang Y, Xu W, Ni P, Li A, Zhou J and Xu
S: miR-99a and miR-491 regulate cisplatin resistance in human
gastric cancer cells by targeting CAPNS1. Int J Biol Sci.
12:1437–1447. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Calin GA, Sevignani C, Dumitru CD, Hyslop
T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M
and Croce CM: Human microRNA genes are frequently located at
fragile sites and genomic regions involved in cancers. Proc Natl
Acad Sci USA. 101:pp. 2999–3004. 2004; View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Karbasy SH, Taheriazam A, Mirghasemi A,
Sedaghati F, Shakeri M, Yahaghi E and Bahador R: RETRACTED ARTICLE:
Upregulation of miR-300 and downregulation of miR-125b act as
potential predictor biomarkers in progression, metastasis, and poor
prognosis of osteosarcoma. Tumour Biol. 2015.(Epub ahead of print).
PubMed/NCBI
|
|
11
|
Zhang Y, Yan LX, Wu QN, Du ZM, Chen J,
Liao DZ, Huang MY, Hou JH, Wu QL, Zeng MS, et al: miR-125b is
methylated and functions as a tumor suppressor by regulating the
ETS1 proto-oncogene in human invasive breast cancer. Cancer Res.
71:3552–3562. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Guan Y, Yao H, Zheng Z, Qiu G and Sun K:
miR-125b targets BCL3 and suppresses ovarian cancer proliferation.
Int J Cancer. 128:2274–2283. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pan S, Cheng X, Chen H, Castro PD, Ittmann
MM, Hutson AW, Zapata SK and Sifers RN: ERManI is a target of
miR-125b and promotes transformation phenotypes in hepatocellular
carcinoma (HCC). PLoS One. 8:e728292013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nishida N, Yokobori T, Mimori K, Sudo T,
Tanaka F, Shibata K, Ishii H, Doki Y, Kuwano H and Mori M: MicroRNA
miR-125b is a prognostic marker in human colorectal cancer. Int J
Oncol. 38:1437–1443. 2011.PubMed/NCBI
|
|
15
|
Amir S, Ma AH, Shi XB, Xue L, Kung HJ and
White RW Devere: Oncomir miR-125b suppresses p14(ARF) to modulate
p53-dependent and p53-independent apoptosis in prostate cancer.
PLoS One. 8:e610642013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yuxia M, Zhennan T and Wei Z: Circulating
miR-125b is a novel biomarker for screening non-small-cell lung
cancer and predicts poor prognosis. J Cancer Res Clin Oncol.
138:2045–2050. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ueda T, Volinia S, Okumura H, Shimizu M,
Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, et al:
Relation between microRNA expression and progression and prognosis
of gastric cancer: A microRNA expression analysis. Lancet Oncol.
11:136–146. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li X, Zhang Y, Zhang H, Liu X, Gong T, Li
M, Sun L, Ji G, Shi Y, Han Z, et al: miRNA-223 promotes gastric
cancer invasion and metastasis by targeting tumor suppressor
EPB41L3. Mol Cancer Res. 9:824–833. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu JG, Wang JJ, Jiang X, Lan JP, He XJ,
Wang HJ, Ma YY, Xia YJ, Ru GQ, Ma J, et al: miR-125b promotes cell
migration and invasion by targeting PPP1CA-Rb signal pathways in
gastric cancer, resulting in a poor prognosis. Gastric Cancer.
18:729–739. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fassan M, Pizzi M, Realdon S, Balistreri
M, Guzzardo V, Zagonel V, Castoro C, Mastracci L, Farinati F, Nitti
D, et al: The HER2-miR125a5p/miR125b loop in gastric and esophageal
carcinogenesis. Hum Pathol. 44:1804–1810. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jin MH, Nam AR, Park JE, Bang JH, Bang YJ
and Oh DY: Resistance mechanism against trastuzumab in
HER2-positive cancer cells and its negation by Src inhibition. Mol
Cancer Ther. pii:molcanther.0669.2016. 2017.
|
|
22
|
Sun R, Shen J, Gao Y, Zhou Y, Yu Z,
Hornicek F, Kan Q and Duan Z: Overexpression of EZH2 is associated
with the poor prognosis in osteosarcoma and function analysis
indicates a therapeutic potential. Oncotarget. 7:38333–38346.
2016.PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bousquet M, Quelen C, Rosati R, Mansat-de
Mas V, La Starza R, Bastard C, Lippert E, Talmant P,
Lafage-Pochitaloff M, Leroux D, et al: Myeloid cell differentiation
arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid
leukemia with the t(2;11)(p21;q23) translocation. J Exp Med.
205:2499–2506. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chapiro E, Russell LJ, Struski S, Cavé H,
Radford-Weiss I, Valle VD, Lachenaud J, Brousset P, Bernard OA,
Harrison CJ and Nguyen-Khac F: A new recurrent translocation
t(11;14)(q24;q32) involving IGH@ and miR-125b-1 in B-cell
progenitor acute lymphoblastic leukemia. Leukemia. 24:1362–1364.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Song F, Yang D, Liu B, Guo Y, Zheng H, Li
L, Wang T, Yu J, Zhao Y, Niu R, et al: Integrated microRNA network
analyses identify a poor-prognosis subtype of gastric cancer
characterized by the miR-200 family. Clin Cancer Res. 20:878–889.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Berg M and Soreide K: EGFR and downstream
genetic alterations in KRAS/BRAF and PI3K/AKT pathways in
colorectal cancer: Implications for targeted therapy. Discov Med.
14:207–214. 2012.PubMed/NCBI
|
|
28
|
Ching CB and Hansel DE: Expanding
therapeutic targets in bladder cancer: The PI3K/Akt/mTOR pathway.
Lab Invest. 90:1406–1414. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Siegfried Z, Bonomi S, Ghigna C and Karni
R: Regulation of the Ras-MAPK and PI3K-mTOR signalling pathways by
alternative splicing in cancer. Int J Cell Biol. 2013:5689312013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schneider MR and Yarden Y: The EGFR-HER2
module: A stem cell approach to understanding a prime target and
driver of solid tumors. Oncogene. 35:2949–2960. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Thiel A and Ristimäki A: Targeted therapy
in gastric cancer. APMIS. 123:365–372. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Teplinsky E and Muggia F: Targeting HER2
in ovarian and uterine cancers: Challenges and future directions.
Gynecol Oncol. 135:364–370. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
D'Amato V, Raimondo L, Formisano L,
Giuliano M, De Placido S, Rosa R and Bianco R: Mechanisms of
lapatinib resistance in HER2-driven breast cancer. Cancer Treat
Rev. 41:877–883. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vilquin P, Donini CF, Villedieu M, Grisard
E, Corbo L, Bachelot T, Vendrell JA and Cohen PA: MicroRNA-125b
upregulation confers aromatase inhibitor resistance and is a novel
marker of poor prognosis in breast cancer. Breast Cancer Res.
17:132015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yagishita S, Fujita Y, Kitazono S, Ko R,
Nakadate Y, Sawada T, Kitamura Y, Shimoyama T, Maeda Y, Takahashi
F, et al: Chemotherapy-regulated microRNA-125-HER2 pathway as a
novel therapeutic target for trastuzumab-mediated cellular
cytotoxicity in small cell lung cancer. Mol Cancer Ther.
14:1414–1423. 2015. View Article : Google Scholar : PubMed/NCBI
|
